Overview

A Study of PTX-200 (Triciribine) Plus Cytarabine in Refractory or Relapsed Acute Leukemia

Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
A phase I-II open label study of PTX-200 in combination with cytarabine in the treatment of relapsed or refractory acute leukemia.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Prescient Therapeutics, Ltd.
Treatments:
Cytarabine